Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)

NCT05599789 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer Metastatic

Interventions

DRUG: Pembrolizumab in Combination with Plinabulin and Docetaxel

Sponsor

Peking Union Medical College Hospital

Collaborators

[object Object]
[object Object]